Immuneering (IMRX) Equity Average (2020 - 2026)

Immuneering's Equity Average history runs 7 years deep, the most recent figure standing at $212.5 million for Q1 2026.

• In Q1 2026, Equity Average rose 410.64% year-over-year to $212.5 million; the TTM figure through Mar 2026 stood at $212.5 million (up 410.64% YoY), while the FY2025 annual figure was $129.9 million, up 96.93% from the prior year.
• Equity Average was $212.5 million for Q1 2026 at Immuneering, down from $223.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $223.2 million in Q4 2025 to a low of $35.4 million in Q2 2025.
• Historically, Equity Average has averaged $109.4 million across 5 years, with a median of $106.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 688.19% in 2022, then sank 51.2% in 2025.
• A 5-year view of Equity Average shows it stood at $115.9 million in 2022, then decreased by 16.03% to $97.3 million in 2023, then plunged by 49.07% to $49.6 million in 2024, then soared by 350.48% to $223.2 million in 2025, then retreated by 4.81% to $212.5 million in 2026.
• The last three Equity Average figures came in at $212.5 million (Q1 2026), $223.2 million (Q4 2025), and $128.5 million (Q3 2025), per Business Quant data.